Florida Trust Wealth Management Co Has $1.69 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Florida Trust Wealth Management Co raised its position in Bristol Myers Squibb Company (NYSE:BMY) by 37.9% during the third quarter, Holdings Channel reports. The institutional investor owned 37,437 shares of the biopharmaceutical company’s stock after buying an additional 10,296 shares during the quarter. Florida Trust Wealth Management Co’s holdings in Bristol Myers Squibb were worth $1,688,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in BMY. Brighton Jones LLC raised its stake in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after buying an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC grew its holdings in Bristol Myers Squibb by 59.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after acquiring an additional 2,786 shares during the period. Focus Financial Network Inc. lifted its stake in shares of Bristol Myers Squibb by 18.4% in the 2nd quarter. Focus Financial Network Inc. now owns 4,815 shares of the biopharmaceutical company’s stock valued at $223,000 after purchasing an additional 747 shares during the period. Sowell Financial Services LLC boosted its position in shares of Bristol Myers Squibb by 1.9% in the 2nd quarter. Sowell Financial Services LLC now owns 56,368 shares of the biopharmaceutical company’s stock worth $2,609,000 after purchasing an additional 1,028 shares during the last quarter. Finally, Lewis Asset Management LLC grew its stake in shares of Bristol Myers Squibb by 53.7% during the second quarter. Lewis Asset Management LLC now owns 9,348 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 3,267 shares during the period. Institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BMY. Citigroup restated a “neutral” rating and set a $53.00 target price (up previously from $45.00) on shares of Bristol Myers Squibb in a report on Wednesday, January 7th. Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. UBS Group raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their target price for the company from $46.00 to $65.00 in a research note on Wednesday, January 7th. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, Guggenheim restated a “buy” rating on shares of Bristol Myers Squibb in a research report on Tuesday, December 23rd. Seven investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $56.86.

Bristol Myers Squibb Stock Down 2.3%

Bristol Myers Squibb stock opened at $55.30 on Tuesday. The company has a 50 day moving average of $52.07 and a 200-day moving average of $48.19. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The stock has a market capitalization of $112.58 billion, a PE ratio of 18.68 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. The business had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The firm’s revenue was up 2.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Friday, January 2nd. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. Bristol Myers Squibb’s dividend payout ratio is 85.14%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.